2-189043249-C-T

Variant summary

Our verdict is Likely benign. Variant got -1 ACMG points: 4P and 5B. PP3_StrongBS1_SupportingBS2

The NM_000393.5(COL5A2):​c.3373G>A​(p.Gly1125Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000514 in 1,459,300 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.000051 ( 0 hom. )

Consequence

COL5A2
NM_000393.5 missense

Scores

17
1
1

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:4

Conservation

PhyloP100: 7.88
Variant links:
Genes affected
COL5A2 (HGNC:2210): (collagen type V alpha 2 chain) This gene encodes an alpha chain for one of the low abundance fibrillar collagens. Fibrillar collagen molecules are trimers that can be composed of one or more types of alpha chains. Type V collagen is found in tissues containing type I collagen and appears to regulate the assembly of heterotypic fibers composed of both type I and type V collagen. This gene product is closely related to type XI collagen and it is possible that the collagen chains of types V and XI constitute a single collagen type with tissue-specific chain combinations. Mutations in this gene are associated with Ehlers-Danlos syndrome, types I and II. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -1 ACMG points.

PP3
MetaRNN computational evidence supports a deleterious effect, 0.945
BS1
Variant frequency is greater than expected in population nfe. gnomad4_exome allele frequency = 0.0000514 (75/1459300) while in subpopulation NFE AF= 0.0000667 (74/1109812). AF 95% confidence interval is 0.0000543. There are 0 homozygotes in gnomad4_exome. There are 33 alleles in male gnomad4_exome subpopulation. Median coverage is 30. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High AC in GnomAdExome4 at 75 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
COL5A2NM_000393.5 linkc.3373G>A p.Gly1125Arg missense_variant Exon 48 of 54 ENST00000374866.9 NP_000384.2 P05997
COL5A2XM_011510573.4 linkc.3235G>A p.Gly1079Arg missense_variant Exon 51 of 57 XP_011508875.1
COL5A2XM_047443251.1 linkc.3235G>A p.Gly1079Arg missense_variant Exon 53 of 59 XP_047299207.1
COL5A2XM_047443252.1 linkc.3235G>A p.Gly1079Arg missense_variant Exon 52 of 58 XP_047299208.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
COL5A2ENST00000374866.9 linkc.3373G>A p.Gly1125Arg missense_variant Exon 48 of 54 1 NM_000393.5 ENSP00000364000.3 P05997
COL5A2ENST00000618828.1 linkc.2212G>A p.Gly738Arg missense_variant Exon 41 of 47 5 ENSP00000482184.1 A0A087WYX9

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD3 exomes
AF:
0.0000279
AC:
7
AN:
250906
Hom.:
0
AF XY:
0.0000295
AC XY:
4
AN XY:
135596
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000617
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000514
AC:
75
AN:
1459300
Hom.:
0
Cov.:
30
AF XY:
0.0000454
AC XY:
33
AN XY:
726148
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000667
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
Cov.:
32
Alfa
AF:
0.0000312
Hom.:
0
Bravo
AF:
0.0000113
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.0000330
AC:
4
EpiCase
AF:
0.00
EpiControl
AF:
0.000237

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Pathogenic:1Uncertain:1
Dec 30, 2021
AiLife Diagnostics, AiLife Diagnostics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jul 15, 2022
GeneDx
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33974636) -

Familial thoracic aortic aneurysm and aortic dissection Uncertain:1
Oct 08, 2024
Ambry Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.G1125R variant (also known as c.3373G>A), located in coding exon 48 of the COL5A2 gene, results from a G to A substitution at nucleotide position 3373. The glycine at codon 1125 is replaced by arginine, an amino acid with dissimilar properties. This variant has been reported in a sudden death cohort and a Ehlers-Danlos syndrome (EDS) genetic testing cohort (Salfati EL et al. Genome Med, 2019 Dec;11:83; Wilson GN et al. Curr Issues Mol Biol, 2024 Mar;46:2620-2643). Internal structural analysis indicates that this alteration disrupts the characteristic G-X-Y motif of the triple helical domain in the COL5A2 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al.Science.1994;266:75-81; Hohenester E et al.Proc. Natl.Acad. Sci.U.S.A.2008;105:18273-7; Ambry internal data). Glycine substitutions in the triple helical domain of COL5A2 have been reported in association with classic Ehlers-Danlos syndrome (cEDS), but the number of affected individuals is limited and several other COL5A2 glycine substitutions in the triple helical domain (e.g., p.G951E and p.G831A) are too common for disease in population databases (Symoens S et al.Hum. Mutat., 2012 Oct;33:1485-93; Ritelli M et al.Orphanet J Rare Dis.2013 Apr;8:58).This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -

Ehlers-Danlos syndrome, classic type, 2 Uncertain:1
Mar 14, 2023
Genetics and Molecular Pathology, SA Pathology
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The COL5A2 c.3373G>A variant is classified as VUS (PM1, PM2, PP3) The COL5A2 c.3373G>A variant is a single nucleotide change in exon 48/54 of the COL5A2 gene, which is predicted to change the amino acid glycine at position 1125 in the protein to arginine. This variant is absent from population databases (PM2). This variant resides in a Collagen triple helix repeat region made of the repetitious amino acid sequence glycine - X - Y, where glycine substitutions are a common cause of disease (PM1). Computational predictions support a deleterious effect on the gene or gene product (PP3). The variant has been reported in dbSNP (rs151187317) and has been reported as Conflicting interpretations of pathogenicity by other diagnostic laboratories (ClinVar Variation ID: 382848). This variant has been detected in HGMD with some degree of doubt over its disease association with a Chiari malformation(CM2115602). -

Ehlers-Danlos syndrome, classic type, 1 Uncertain:1
Jan 20, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1125 of the COL5A2 protein (p.Gly1125Arg). This variant is present in population databases (rs151187317, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with COL5A2-related conditions. ClinVar contains an entry for this variant (Variation ID: 382848). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt COL5A2 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
1.0
BayesDel_addAF
Pathogenic
0.46
D
BayesDel_noAF
Pathogenic
0.60
CADD
Pathogenic
28
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.90
D;T;D
Eigen
Pathogenic
1.0
Eigen_PC
Pathogenic
0.93
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Pathogenic
0.98
.;D;D
M_CAP
Pathogenic
0.46
D
MetaRNN
Pathogenic
0.95
D;D;D
MetaSVM
Pathogenic
0.99
D
MutationAssessor
Pathogenic
4.1
H;.;H
PrimateAI
Pathogenic
0.90
D
PROVEAN
Pathogenic
-7.2
D;.;.
REVEL
Pathogenic
1.0
Sift
Pathogenic
0.0
D;.;.
Sift4G
Pathogenic
0.0010
D;D;.
Polyphen
1.0
D;.;D
Vest4
0.98
MutPred
0.99
Gain of MoRF binding (P = 0.0137);.;Gain of MoRF binding (P = 0.0137);
MVP
1.0
MPC
0.31
ClinPred
1.0
D
GERP RS
5.2
Varity_R
0.97
gMVP
0.98

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs151187317; hg19: chr2-189907975; API